Skip to main content

Table 4 Predictors of HBV screening a by cancer type

From: Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center

Predictor Hematologic malignancy (N = 3657) Solid tumorb(N =15,031)
  Screened Univariate logistic regression Multiple logistic regression OR Screened Univariate logistic regression Multiple logistic regression
  (N=2439) (66.7%) OR (95% CI) P value (95% CI) P value (N=581) (3.9%) OR (95% CI) P value OR (95% CI) P value
Age, years, mean (SD) 52.5 (15.5) 0.99 (0.99–1.0) 0.005 0.99 (0.98–0.99) 0.0001 52.4 (15.0) 0.98 (0.98–0.99) <0.0001 0.98 (0.97–0.98) <0.0001
Sex, no. (%)           
 Male 1418/2133 (66.5) Ref. - - - 297/5947 (5.0) Ref. - Ref. -
 Female 1021/1524 (67.0) 1.0 (0.89–1.2) 0.74 - - 284/9084 (3.1) 0.61 (0.52–0.73) <0.0001 0.58 (0.49–0.70) <0.0001
Race/ethnicity, no. (%)           
 White 1776/2645 (67.2) Ref. - Ref. - 392/10,523 (3.7) Ref. - - -
 Hispanic 324/486 (66.7) 0.98 (0.80–1.2) 0.84 0.92 (0.75–1.1) 0.45 78/1833 (4.3) 1.1 (0.90–1.5) 0.27 - -
 Black 196/333 (58.9) 0.70 (0.56–0.88) 0.003 0.69 (0.55–0.88) 0.002 51/1759 (2.9) 0.77 (0.57–1.0) 0.09 - -
 Asian 41/50 (82.0) 2.2 (1.1–4.6) 0.03 2.0 (0.98–4.3) 0.06 35/458 (7.6) 2.1 (1.5–3.1) <0.0001 - -
 Other 102/143 (71.3) 1.2 (0.8–1.8) 0.23 1.0 (0.72–1.6) 0.79 25/458 (5.5) 1.5 (0.98–2.3) 0.06 - -
Residence, no. (%)           
 US 2332/3510 (66.4) Ref. - - - 564/14,580 (3.9) Ref. - Ref. -
 Outside US 107/147(72.8) 1.4 (0.93–2.0) 0.11 - - 17/451 (3.8) 0.97 (0.59–1.6) 0.92 0.51 (0.30–0.90) 0.02
HBV risk factor, no. (%)           
 No 1683/2603 (64.7) Ref. - Ref. - 321/10,694 (3.0) Ref. - Ref.  
 Yes 756/1054 (71.7) 1.4 (1.2–1.6) <0.0001 1.3 (1.1–1.5) 0.001 260/4337 (6.0) 2.1 (1.7–2.4) <0.0001 2.5 (2.1–3.0) <0.0001
Chemotherapy type, no. (%)           
 Non-rituximab 1191/1854 (64.2) Ref. - Ref. - 469/14,857 (3.2) Ref. - Ref. -
 Rituximab 1248/1803 (69.2) 1.2 (1.1–1.4) 0.001 1.3 (1.2–1.5) <0.0001 112/174 (64.4) 55.4 (40.1–76.6) <0.0001 62.0 (44.1–87.0) <0.0001
Timing of first chemotherapyc           
 Period 1 1428/2312 (61.8) Ref. - Ref. - 326/9521 (3.4) Ref. - Ref. - 
 Period 2 829/1101 (75.3) 1.9 (1.6–2.2) <0.0001 2.0 (1.6–2.3) <0.0001 208/4602 (4.5) 1.3 (1.1–1.6) 0.001 1.3 (1.1–1.6) 0.003
 Period 3 182/244 (74.6) 1.8 (1.4–2.4) <0.0001 1.9 (1.4–2.6) <0.0001 47/908 (5.2) 1.5 (1.1–2. 1) 0.007 1.7 (1.2–2.3) 0.003
  1. Abbreviations: HBV hepatitis B virus, OR odds ratio, CI confidence interval, Ref., reference.
  2. aHBV screening means that both hepatitis B surface antigen (HBsAg) test and antibody to hepatitis B core antigen (anti-HBc) test were ordered.
  3. bExcludes patients with primary liver cancer.
  4. cPeriod 1: 1/1/04 through 12/18/2008; period 2, 12/19/2008 through 9/30/2010; period 3, 10/1/2010 through 4/30/11.